These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1979217)

  • 21. MDMA transiently alters biogenic amines and metabolites in mouse brain and heart.
    Steele TD; Nichols DE; Yim GK
    Pharmacol Biochem Behav; 1989 Oct; 34(2):223-7. PubMed ID: 2576134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pineal serotonin is resistant to depletion by serotonergic neurotoxins in rats.
    Champney TH; Matthews RT
    J Pineal Res; 1991; 11(3-4):163-7. PubMed ID: 1724461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.
    McCann UD; Ricaurte GA
    J Clin Psychopharmacol; 1993 Jun; 13(3):214-7. PubMed ID: 8102623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine.
    Nash JF; Yamamoto BK
    Brain Res; 1992 May; 581(2):237-43. PubMed ID: 1356579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations.
    Ricaurte GA; Finnegan KT; Irwin I; Langston JW
    Ann N Y Acad Sci; 1990; 600():699-708; discussion 708-10. PubMed ID: 1701292
    [No Abstract]   [Full Text] [Related]  

  • 26. The interactions of MK-801 with the amphetamine analogues D-methamphetamine (D-METH), 3,4-methylenedioxymethamphetamine (D-MDMA) or D-fenfluramine (D-FEN): neural damage and neural protection.
    Miller DB; O'Callaghan JP
    Ann N Y Acad Sci; 1993 May; 679():321-4. PubMed ID: 8099774
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans.
    Ricaurte GA; McCann UD
    Ann N Y Acad Sci; 1992 May; 648():371-82. PubMed ID: 1379014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ["Ecstasy" and "ice": the return of the amphetamines].
    Kaminer Y; Zemishlany Z
    Harefuah; 1991 Jun; 120(12):727-9. PubMed ID: 1683637
    [No Abstract]   [Full Text] [Related]  

  • 29. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration.
    Ricaurte GA; DeLanney LE; Irwin I; Langston JW
    Brain Res; 1988 Apr; 446(1):165-8. PubMed ID: 2897228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychostimulant properties of MDMA.
    Gold LH; Geyer MA; Koob GF
    NIDA Res Monogr; 1989; 95():345-6. PubMed ID: 2577038
    [No Abstract]   [Full Text] [Related]  

  • 31. Neurochemistry and neurotoxicity of substituted amphetamines.
    Wagner J; Peroutka SJ
    Neuropsychopharmacology; 1990 Jun; 3(3):219-20. PubMed ID: 1973040
    [No Abstract]   [Full Text] [Related]  

  • 32. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain.
    Hegadoren KM; Baker GB; Coutts RT
    J Pharmacol Toxicol Methods; 1995 Oct; 34(2):117-23. PubMed ID: 8563033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys.
    Kleven MS; Woolverton WL; Seiden LS
    Brain Res; 1989 May; 488(1-2):121-5. PubMed ID: 2472850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurotoxicity of MDMA and related compounds: anatomic studies.
    Molliver ME; Berger UV; Mamounas LA; Molliver DC; O'Hearn E; Wilson MA
    Ann N Y Acad Sci; 1990; 600():649-61; discussion 661-4. PubMed ID: 1979216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylenedioxyamphetamine: neurotoxic effects on serotonergic projections to brainstem nuclei in the rat.
    Harvey JA; McMaster SE; Romano AG
    Brain Res; 1993 Aug; 619(1-2):1-14. PubMed ID: 7690669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors.
    Schmidt CJ; Black CK; Abbate GM; Taylor VL
    Brain Res; 1990 Oct; 529(1-2):85-90. PubMed ID: 1980848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA.
    Steele TD; Brewster WK; Johnson MP; Nichols DE; Yim GK
    Pharmacol Biochem Behav; 1991 Feb; 38(2):345-51. PubMed ID: 1676172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs.
    Grob CS; Bravo GL; Walsh RN; Liester MB
    J Nerv Ment Dis; 1992 Jun; 180(6):355-6. PubMed ID: 1350614
    [No Abstract]   [Full Text] [Related]  

  • 39. Behavioral and developmental effects of two 3,4-methylenedioxymethamphetamine (MDMA) derivatives.
    Bronson ME; Barrios-Zambrano L; Jiang W; Clark CR; DeRuiter J; Newland MC
    Drug Alcohol Depend; 1994 Dec; 36(3):161-6. PubMed ID: 7889806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys.
    Insel TR; Battaglia G; Johannessen JN; Marra S; De Souza EB
    J Pharmacol Exp Ther; 1989 Jun; 249(3):713-20. PubMed ID: 2471824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.